Q1 EPS Estimate for NewAmsterdam Pharma Reduced by Analyst

NewAmsterdam Pharma (NASDAQ:NAMS) – Stock analysts at William Blair decreased their Q1 2025 EPS estimates for shares of NewAmsterdam Pharma in a report released on Wednesday, February 26th. William Blair analyst M. Phipps now anticipates that the company will earn ($0.51) per share for the quarter, down from their prior forecast of ($0.49). The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.75) per share. William Blair also issued estimates for NewAmsterdam Pharma’s Q2 2025 earnings at ($0.52) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.55) EPS, FY2025 earnings at ($2.11) EPS, Q1 2026 earnings at ($0.54) EPS, Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.56) EPS, FY2026 earnings at ($2.18) EPS, FY2027 earnings at ($2.49) EPS and FY2028 earnings at ($1.83) EPS.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The firm had revenue of $12.77 million for the quarter, compared to analyst estimates of $3.30 million.

Several other research firms have also recently commented on NAMS. Scotiabank raised their target price on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a research note on Thursday, February 27th. Royal Bank of Canada reissued an “outperform” rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Needham & Company LLC reduced their target price on NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating for the company in a report on Thursday, February 27th. Finally, HC Wainwright reiterated a “buy” rating and issued a $48.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $43.80.

NewAmsterdam Pharma Price Performance

NewAmsterdam Pharma stock opened at $21.50 on Monday. The business has a 50 day simple moving average of $22.35 and a 200-day simple moving average of $20.39. NewAmsterdam Pharma has a 12 month low of $15.19 and a 12 month high of $27.29. The stock has a market capitalization of $1.99 billion, a PE ratio of -8.27 and a beta of -0.06.

Insider Buying and Selling at NewAmsterdam Pharma

In related news, major shareholder Nap B.V. Forgrowth sold 100,728 shares of NewAmsterdam Pharma stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $26.10, for a total transaction of $2,629,000.80. Following the completion of the sale, the insider now owns 10,908,502 shares in the company, valued at approximately $284,711,902.20. This trade represents a 0.91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last three months, insiders sold 404,927 shares of company stock worth $10,390,787. 19.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of the company. GF Fund Management CO. LTD. acquired a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth $50,000. Frazier Life Sciences Management L.P. increased its stake in shares of NewAmsterdam Pharma by 23.8% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 15,916,418 shares of the company’s stock valued at $409,052,000 after acquiring an additional 3,061,224 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of NewAmsterdam Pharma by 6.0% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 253,571 shares of the company’s stock worth $6,517,000 after acquiring an additional 14,288 shares during the period. Voloridge Investment Management LLC purchased a new position in shares of NewAmsterdam Pharma in the 4th quarter worth about $721,000. Finally, Woodline Partners LP grew its holdings in shares of NewAmsterdam Pharma by 108.7% during the 4th quarter. Woodline Partners LP now owns 2,430,782 shares of the company’s stock worth $62,471,000 after purchasing an additional 1,266,105 shares during the period. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.